Hemolytic Uremic Syndrome in Pregnancy and Postpartum

Clinical journal of the American Society of Nephrology: CJASN

Alexandra Bruel¹ 

[1]Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...Due to the number of contributing authors, the affiliations are provided in the Supplemental Material...

关键词: hemolytic uremic syndrome;    complement;    pregnancy;    thrombotic microangiopathy;    Antibodies, Monoclonal, Humanized;    Atypical Hemolytic Uremic Syndrome;    Complement Pathway, Alternative;    Female;    Follow-Up Studies;    France;    Humans;    Italy;    Kidney Failure, Chronic;    kidney transplantation;    Plasma Exchange;    Postpartum Period;    Pregnancy;    Recurrence;    renal dialysis;    Retrospective Studies;    Thrombotic Microangiopathies;    United Kingdom;    chemotactic factor inactivator;    eculizumab;   

DOI  :  10.2215/CJN.00280117

学科分类：泌尿医学

来源: American Society of Nephrology

【 摘 要 】

Background Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of atypical hemolytic uremic syndrome linked to complement alternative pathway dysregulation.Design, setting, participants, & measurements We sought to retrospectively analyze the presentation, outcome, and frequency of complement alternative pathway gene variants in a larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-associated hemolytic uremic syndrome.Results Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and in the postpartum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six (78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions, and four (5%) received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients reached ESRD, 15 (19%) had CKD, and 18 (28%) patients experienced hemolytic uremic syndrome relapse. Twenty-four patients (27%) received a kidney transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) patients. Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) and CFI genes (9%).Conclusions Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic uremic syndrome nonrelated to pregnancy have the same severity at onset and during follow-up and the same frequency of complement gene variants.

【 授权许可】

CC BY